To test whether the blockade of CD158ab/KIRDL-1,-2/3 might facilitate the activation and cytotoxic potential of tumor-derived NK-cells, IL-2 preactivated TIL from GBM patients were preincubated with a human IgG4 isotype control mAb or Lirilumab (anti-KIR2DL-1,-2/3) and cocultured with IFN-γ pretreated HLA-C expressing K562 cells (K562-HLA-C) or HLA class-I deficient K562 cells (K562-0). This evidence concerns the gene KIR2DL1 and neoplasm.